Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 23, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for October 17, 2007 Subscribe to this News Feed      
 

'Sinus Science Pharmacy' Observes Positive Patient Outcomes when Patients Inhale Corticosteroids and Amphotericin B

Aerosol Science Laboratories, ASL Pharmacy a pharmacy that specializes in sinus care, has observed that patients respond positively to inhaled corticosteroids and Amphotericin B after 21 days of therapy. With more doctors focusing on treating the inflammation caused by sinus infections, rather than treating the infection itself, ASL Pharmacy can concur with physicians that a sequential therapy of corticosteroid followed by Amphotericin B (thought to possess anti-inflammatory properties of its own) has produced positive results in its patients. Because medication is inhaled rather than swallowed, more medication travels to the site of infection and less medication is absorbed into the bloodstream.
When patients have tried traditional therapies, like high dose oral meds, spray bottles or irrigations and have not seen positive results, aerosol therapy starts to make a whole lot of sense for patients with chronic sinusitis.

Camarillo, CA (PRWEB) October 17, 2007 -- Aerosol Science™ Laboratories ASL Pharmacy announces today sequential aerosol therapy administering corticosteroids and Amphotericin B produces positive patient outcomes. At the recent AAO-HNS convention in Washington DC, several leaders in the industry indicated that Chronic Sinus Infections could be the result of a specific inflammatory response to allergens within the sinus cavities. In addition to topical corticosteroids, evidence was presented indicating Amphotericin B may also possess certain anti-inflammatory properties.

News Image

ASL Pharmacy™ (a pharmacy specializing in sinus medications) has observed in patients positive responses to aerosolized corticosteroids such as Betamethasone, Budesonide and Mometasone followed by Amphotericin B. This aerosolized intranasal therapy is an easy to use alternative approach for successfully treating inflammation. These observations augment a growing body of evidence that supports topical medications for the treatment of the inflammation associated with CRS, AFS, PAR and Sinus Polyps.

What makes aerosol therapy unique is that patients inhale their medications through their noses for better medication deposition into their sinuses. The medication "mist" is only 3.1 microns in diameter, which is literally 50 times smaller than the typical spray bottle. The medication travels directly to the site of infection so more medication treats the inflammation and less medication is absorbed into the body.

"I have patients call me everyday telling me that this is the only therapy that has ever worked for them," states Cal Tarrant, CMO for Aerosol Science Labs. "When patients have tried traditional therapies, like high dose oral meds, spray bottles or irrigations and have not seen positive results, aerosol therapy starts to make a whole lot of sense for patients with chronic sinusitis."

Following are a few facts regarding ASL's sequential aerosol therapy:

a.Dose: 0.25-0.6 mg (steroid) and 5-10 mg (anti-fungal) - Initial Tx BID to TID x 21 days
b.Tx Time: Each individual dose aerosolizes in approximately 2.5-3.5 min. respectively These sequentially administered meds aerosolize in approximately 6 min.
c.Deposition: Aerosolized Amphotericin B stays in the sinuses and does not flow out, which improves medication deposition and patient compliance
d.Compliance: We have observed excellent patient acceptance of prescribed dual therapy resulting in successful patient outcomes
e.Frequency: TID dosing including an easy to administer "mid-day" dose equates to less than 20 minutes per day
f.Maintenance: When symptoms subside, patient may be maintained on an anti-inflammatory at a reduced frequency

Aerosol Science™ is excited to share their observations, which concur with and support recent industry developments and physician opinion. Please visit Sinus Science or give our office a call at 866-552-7579 to find out more about aerosolized topical intranasal sinus medications. Our therapies require a prescription, are covered by most drug plans and can be shipped directly to patients overnight.

About Aerosol Science Laboratories Inc. and ASL Pharmacy:
Aerosol Science Laboratories Inc. is a privately held specialty pharmacy, which makes compounded sinus medications specifically for patients with Chronic Sinusitis, Perennial Allergic Rhinitis, Allergic Fungal Sinusitis and Sinus Polyps. All dispensed medications require a prescription, which are usually written by ENTs and Allergists. However, any MD, DO, DDS or NP can write this prescription. For more information contact: Cal Tarrant @ 866-552-7579 x223, Aerosol Science Laboratories, Inc., Camarillo, CA.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/TWFnbi1Mb3ZlLVByb2YtVGhpci1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
CAL TARRANT
Aerosol Science Laboratories Inc.
805-236-1679
Email us Here
ATTACHED FILES

Rx Form

Rx Form
Medications Available

Sinus Science Nebulizer

Sinus Science Nebulizer
CAD image of original Sinus Science design.

Press Release Attachment

Press Release Attachment

Press Release Attachment

Press Release Attachment

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright